A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 309 participants.
Also called NCT01475825
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 309 participants
- Sponsor
- Kastle Therapeutics, LLC
- Registry
-
NCT01475825 -
2011-001480-42
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Croatia, Czechia, Denmark, Germany, Greece, Hong Kong SAR China, Hungary, India, Israel, Italy, Malaysia, Netherlands, New Zealand, Norway, Poland, Russia, South Africa, South Korea, Spain, Sweden, Taiwan, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01475825. Randomized; quadruple masking; primary purpose treatment. Start 2011-12 (actual); primary completion 2015-12-29 (actual). Results posted on 2019-03-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
- Acronym
- FOCUS FH
- Condition
- Hypercholesterolemia
- Condition
- Heterozygous Familial
- Intervention (Drug)
- mipomersen sodium 200 mg
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- mipomersen sodium 70 mg
- Lead sponsor
- Kastle Therapeutics, LLC
Record details
- Record id
cardio:ct-nct01475825- Content hash
121076dead6cbc7835b8c9ee4581246d14dbf8bd7a13c36baaa611f5303c5c1f